Clinical Trials, Phase II as Topic Concept

subject area of

• A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura  Conferences
• A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer  Journal Articles
• A Replacement for Warfarin  Journal Articles
• A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials  Journal Articles
• A multi-centre, participant-blinded, randomized, 3-year study to compare the efficacy of Virtual Surgical Planning (VSP) to Freehand Surgery (FHS) on bony union and quality of life outcomes for mandibular reconstruction with fibular and scapular free flaps: study protocol for a randomized phase II/III trial.  Journal Articles
• A phase 2 study of stereotactic body radiation therapy for squamous cell carcinoma of the head and neck (SHINE): a single arm clinical trial protocol  Journal Articles
• A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy  Journal Articles
• Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination  Journal Articles
• Advances in Antithrombotic Therapy: Novel Agents  Journal Articles
• An estimate of the cost of conducting phase II trials in lung cancer  Journal Articles
• Andexanet alfa for the treatment of hemorrhage  Journal Articles
• Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves  Journal Articles
• Apixaban in Acute Coronary Syndromes  Journal Articles
• CCI-779 Wyeth.  Journal Articles
• Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum  Journal Articles
• Challenges in the conduct and interpretation of phase II (pilot) randomized trials  Journal Articles
• Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor)  Journal Articles
• Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy  Journal Articles
• Clinical trial design in metastatic breast cancer: a commentary.  Journal Articles
• Colchicine pre-treatment and post-treatment does not worsen bleeding or functional outcome after collagenase-induced intracerebral hemorrhage  Journal Articles
• Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors.  Journal Articles
• Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens  Conferences
• Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma  Journal Articles
• Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome  Journal Articles
• Current Incidence and Outcomes of Gastrointestinal Mesenchymal Tumors Including Gastrointestinal Stromal Tumors  Journal Articles
• DNA methyltransferase inhibitors—state of the art  Journal Articles
• Dabigatran Etexilate: Future Directions in Anticoagulant Treatment  Journal Articles
• Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria  Journal Articles
• Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis  Journal Articles
• Drug evaluation: E-5564.  Journal Articles
• Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy  Journal Articles
• Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination  Journal Articles
• Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors  Journal Articles
• Fondaparinux, the first selective factor Xa inhibitor  Journal Articles
• Generalisability of pharmaceutical randomised controlled trial eligibility criteria for progressive pulmonary fibrosis.  Journal Articles
• Heterogeneity among lists of cautioned or prohibited drugs in protocols of early-phase oncology trials  Journal Articles
• Human Gene Marker/Therapy Clincal Protocols (Complete Updated Listings)  Journal Articles
• Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.  Journal Articles
• Impact of Response to Prior Chemotherapy in Patients With Advanced Urothelial Carcinoma Receiving Second-Line Therapy: Implications for Trial Design  Journal Articles
• Impact of the Number of Prior Lines of Therapy and Prior Perioperative Chemotherapy in Patients Receiving Salvage Therapy for Advanced Urothelial Carcinoma: Implications for Trial Design  Journal Articles
• Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute-Sponsored Trials  Journal Articles
• Importance of infarct topography in determination of stroke mechanism and recurrence risk: a post-hoc analysis of the dabigatran acute treatment of stroke trial.  Journal Articles
• Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma  Journal Articles
• Incidence of delayed venous thromboembolic events in patients undergoing abdominal and pelvic surgery for cancer: a systematic review and meta‐analysis  Journal Articles
• Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design  Journal Articles
• Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma  Journal Articles
• Investigating the appropriateness of different concordance measures in a time‐to‐event setting  Journal Articles
• Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial  Journal Articles
• Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials  Conferences
• Management of Patients with Acute Coronary Syndromes  Journal Articles
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report  Journal Articles
• New Anticoagulant Drugs  Journal Articles
• New Anticoagulants for Treatment of Venous Thromboembolism  Journal Articles
• New Antithrombotic Drugs  Journal Articles
• Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents  Journal Articles
• Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval  Journal Articles
• Optimizing vaccine-induced CD8⁺T-cell immunity: focus on recombinant adenovirus vectors  Journal Articles
• Otamixaban in acute coronary syndromes  Journal Articles
• Our Choice: study protocol for a randomized controlled trial for optimal implementation of psoriasis treatment by the integration of Chinese and western medicine  Journal Articles
• Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer  Journal Articles
• Overview of the New Oral Anticoagulants  Journal Articles
• Panorama From the Oncolytic Virotherapy Summit  Journal Articles
• Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma  Journal Articles
• Pentasaccharide Org31540/SR90107A clinical trials update: Lessons for practice  Journal Articles
• Phase 2 Vitamin C Sepsis Trials: Another Brick in the (Evidence) Wall?*  Journal Articles
• Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival  Journal Articles
• Phase II Stopping Rules That Employ Response Rates and Early Progression  Journal Articles
• Placebo Rates in Crohn's Disease Randomized Clinical Trials: An Individual Patient Data Meta-Analysis.  Journal Articles
• Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy  Journal Articles
• Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab  Journal Articles
• Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism  Journal Articles
• Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma  Journal Articles
• Proton pump inhibitors: the beginning of the end or the end of the beginning?  Journal Articles
• Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials  Journal Articles
• Randomized Phase II Trials: Inevitable or Inadvisable?  Journal Articles
• Randomized, controlled clinical trials in sepsis: Has methodological quality improved over time?  Journal Articles
• Remote ischemic conditioning in necrotizing enterocolitis: study protocol of a multi-center phase II feasibility randomized controlled trial  Journal Articles
• Response of Primary Renal Cell Carcinoma to Systemic Therapy  Journal Articles
• Rolapitant for the Treatment of Chemotherapy-Induced Nausea and Vomiting: A Review of the Clinical Evidence  Journal Articles
• Safety Outcomes in Meta-analyses of Phase 2 vs Phase 3 Randomized Trials  Journal Articles
• Seeking informed consent to cancer clinical trials:  Journal Articles
• Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma  Journal Articles
• Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.  Journal Articles
• Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials  Journal Articles
• Study protocol of a phase 2, randomised, placebo-controlled, double-blind, adaptive, parallel group clinical study to evaluate the efficacy and safety of recombinant alpha-1-microglobulin in subjects at high risk for acute kidney injury following open-chest cardiac surgery (AKITA trial)  Journal Articles
• Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy  Journal Articles
• Systematic Chemotherapy for Inoperable, Locally Advanced, Recurrent, or Metastatic Uterine Leiomyosarcoma: A Systematic Review  Journal Articles
• Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review  Journal Articles
• Systemic therapy for advanced uterine sarcoma: A systematic review of the literature  Journal Articles
• Systemic therapy in the curative treatment of head and neck squamous cell cancer: A systematic review  Journal Articles
• The Role of Gemcitabine in the Treatment of Cholangiocarcinoma and Gallbladder Cancer: A Systematic Review  Journal Articles
• The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma: A Systematic Review and Practice Guideline  Journal Articles
• The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.  Journal Articles
• Treatment Strategies in Elderly Patients with Aggressive Histology Lymphoma  Journal Articles
• Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline  Journal Articles
• Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials  Journal Articles
• [¹⁸F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial  Journal Articles